Viking Therapeutics (VKTX) stock surges after phase 2 Venture trial meets primary and secondary endpoints
Tweet Send to a Friend
Viking Therapeutics (NASDAQ: VKTX) shares surged more than 80% premarket Monday after the company announced positive top-line results from its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
